Citations

Clear

3057 citation(s) found for "Cd, Johnson".

Establishing Reference Values in Healthy Participants for the Cardiac Troponin T High-Sensitivity Gen 6 Assay: REF-TSIX Global Reference Study
Daniels, Lori B. , Mueller, Christian, Giannitsis, Evangelos, Meex, Steven J. R., Buehlmann, David, Dilba, Peter, Bendig, Garnet, Cole, Mette, Body, Richard, Christenson, Robert H, deFilippi, Christopher R, Inoue, Kenji, Jaffe, A S, McCarthy, Cian P. , McCord, J., Neumann, Johannes T, Omland, T., Papendick, Cynthia , Sandoval, Yader, Twerenbold, Raphael, Peacock, W Frank, Mills, Nicholas L, investigators, the TSIX, Jacobs, Michael B., Lucksinger, Gregg, Powell, Richard, Johnson, Daniel, Coleman, Hugh, Fein, M, Surber, Joseph, Vu, Jack B., Hassman, Michael, Hernandez, John, Kirstein, Judith, Tomaszewski, Christian, Runyon, Michael S. , Gong, Jonathan , Wein, D., Andrabi, Sara , Kopin, David , Larrain, Germain, Tahirkheli, Naheem, Clemency, Brian, Abdullah, Shuaib, Hira, Ravi S. , Klausner, H A, Mahler, Simon A. , Crystal, Chad, Headden, Gary, Chaille, Peter, Cannon, Chad Aaron, Limkakeng, Alexander, Tolia, Vaishal , Knapp, Barry J., Massoomi, Mohammad, Sandoval, Yader, Ko, Emily, Luzzi, Verónica, Christenson, Robert, Carson, Jennifer Powers , Cacioppo, F , Kolev, E., Petrov, Andrey, Hazarbasanov, Dobri , Simova, lana, Magimaiseelan, Luci Suganthi, Kosch, Christine, Klein, G, Mehltretter, Kai, Sauter, Joachim, Baumann, Sybille, Moeckel, Martin, Twerenbold, Raphael, Muller-Hennessen, Matthias, Biener, Moritz , Findeisen, P., Omland, Torbjøm, Wilczek-Kosowska, Urszula, Zimmer-Satora, Ewa, Krecipro-Nizińska, Ewa, Miró, O, Díaz, Víctor Jiménez , Mueller, C, Christ, Michael, Lynch, Stephen, BODY, R. A. F., Matsuki, Shunji, Eto, Takashi, Tanaka, Takanori, Hanada, Ryuzo, Nakagami, Takuo, Nakama, T, Kadota, K., Jing, Shan, Yu, Shuwen, Zhang, Hongxuan, Zhang, Jun, Huo, Yong, Zhang, Yan, Yan, Li, Jiang, Longyuan, Chen, Weiqiang, Huang, Jianying, Zhao, Yan, Guan, Ling, Yang, Yanhua, Zhang, Qin, Qiu, Zhaohui, Body, Richard , Neumann, Franz–Josef , Müller, Christian , Mueller, Christian , Body, Rick , Eggers, Kai M. , Jaffe, Allan S. , Neumann, Johannes T , Sandoval, Yader , Tan, Jack Wei Chieh , Than, Martin , Twerenbold, Raphael , Mills, Nicholas L , Daniels, Lori B , Giannitsis, Evangelos , Meex, Steven J.R. , Christenson, Robert H. , Cobbaert, Christa M. , deFilippi, Christopher R. , McCord, James , Omland, Torbjørn , Sandoval, Yader , Tan, Jack Wei Chieh , Than, Martin , Twerenbold, Raphael , Surber, Joseph, Tomaszewski, Christian, Clemency, Brian, Headden, Gary , Cannon, Chad, Knapp, Barry , Tran, Nam K , Niederdöckl, Jan Daniel , Kolev, Emil, Popov, Todor, Sauter, Joachim, Baumann, Sybille , Möeckel, Martin , Müller‐Hennessen, Matthias, Findeisen, Peter, Scharnhorst, Volkher , Omland, T, Krecipro-Nizińska, Ewa, Christ, Michael , Nakagami, Takuo, Huo, Yong

Mayo Clinic

Clinical Chemistry | January 18, 2026 | Volume: 72 | Issue: 4 | Pages: 488-502

10.1093/clinchem/hvag011 | PMID 41564003 Get It

Abstract Background Measurement of cardiac troponin (cTn) using high-sensitivity assays is recommended for the diagnosis of myocardial infarction. We determined sex-specific and uniform 99th percentile upper reference limits (URLs) using the new Elecsys® Troponin T high-sensitivity Gen 6 assay in a global, healthy reference range cohort. Methods Lithium-heparin plasma and serum samples were prospectively collected from apparently healthy individuals aged ≥20 years across 34 global sites in the United States, Europe, China, and Japan. cTnT was measured using the Troponin T high-sensitivity Gen 6 assay on the Cobas® e 801 analyzer. Exclusion criteria were defined according to the 2022 IFCC guidance. Uniform and sex-specific 99th percentile URLs and nonparametric 95% CIs were determined in plasma and serum separately and combined. Results The final study population comprised 4147 participants (52.5% female) with a median (25th–75th percentiles) age of 48.0 (33.0–59.0) years; 45.8%, 47.9%, 5.2%, and 1.1% were White, Asian, Black, and other/unknown, respectively. For sample matrices combined (n = 8294), 81.0% and 99.2% of cTnT values were above the limit of detection in females and males, respectively. Sex-specific 99th percentile URLs (95% CI) were 18 (16–23) ng/L for females and 32 (28–35) ng/L for males; the uniform 99th percentile URL was 27 (24–31) ng/L. URLs were comparable in plasma and serum samples. Conclusions This study determined sex-specific and uniform 99th percentile URLs for the Troponin T high-sensitivity Gen 6 assay that were comparable irrespective of the matrix used in a large, global, healthy reference population.
Alzheimer's disease polygenic risk in early‐ and late‐onset Alzheimer's disease
Pentchev, Julian V., Jackson, Trever, Khan, Naazneen , Rosewood, Thea , Huang, Yen‐Ning, Nho, Kwangslk, Saykin, Andrew J., Eloyan, Ani, Taurone, Alexander, Thangarajah, Maryanne, Riddle, Meghan, Salloway, Steven, Atri, Alireza, Honig, Lawrence S., Johnson, Erik C. B., Turner, Raymond Scott, Masdeu, Joseph C. , Foroud, Tatiana M., Clark, David, Hammers, Dustin B., Dage, Jeffrey L., Kirby, Kala, Ghetti, Bernardino, Newell, Kathy, Onyike, Chiadi U., Day, Gregory S., Graff‐Radford, Neill R., Murray, Melissa E., Jones, D. Richard, Jack, Clifford R., Vemuri, Prashanthi, Touroutoglou, Alexandra, Duara, Ranjan, Grant, Ian, Sha, Sharon, Wingo, Thomas S., Beckett, Laurel A., Rogalski, Emily J, Mendez, Mario F., Kramer, Joel, Joie, Renaud La, Grinberg, Lea T., Koeppe, Robert, Wolk, David A., Aisen, Paul, RAMAN, REMA , Toga, Arthur, Kukull, Walter A., Musiek, Erik, Womack, Kyle, Carrillo, Maria C., Rabinovici, Gil D., Dickerson, Bradford C., Apostolova, Liana G., Nudelman, Kelly N. H., Murray, Melissa E. , Carrillo, María C. , Turner, Raymond Scott , Rabinovici, Gil D. , Joie, Renaud La , Day, Gregory S. , Day, Gregory S , Murray, Melissa E , La Joie, Renaud , Rabinovici, Gil D , Huang, Yen‐Ning, Nho, Kwangsik T. , Saykin, Andrew J. , Eloyan, Ani , Taurone, Alexander, Riddle, Meghan , Salloway, Steve , Atri, Alireza , Honig, Lawrence S. , Johnson, Erik C. B. , Masdeu, Joseph C , Foroud, Tatiana , Clark, David, Hammers, Dustin B , Dage, Jeffrey L. , Ghetti, Bernardino , Newell, Kathy L. , Onyike, Chiadi U. , Graff‐Radford, Neill R. , Jones, David T. , Jack, Clifford R. , Vemuri, Prashanthi , Touroutoglou, Alexandra , Duara, Ranjan , Sha, Sharon J. , Beckett, Laurel , Rogalskı, Emily , Mendez, Mario F. , Kramer, Joel, Blazhenets, Ganna , Grinberg, Lea T. , Koeppe, Robert A. , Wolk, David A. , Aisen, Paul , Toga, Arthur W. , Kukull, Walter A. , Musiek, Erik , Dickerson, Bradford Clark , Apostolova, Liana G. , Nudelman, Kelly

Mayo Clinic

Alzheimer's & Dementia | January 14, 2026 | Volume: 22 | Issue: 1 | Pages: No page available

10.1002/alz.71066 | PMID 41532810 Get It

Abstract INTRODUCTION The genetic basis of sporadic early‐onset Alzheimer's disease (EOAD) remains largely unknown, prompting evaluation of late‐onset Alzheimer's disease (LOAD) polygenic risk in EOAD. METHODS A LOAD polygenic score (PGS) was calculated in the Longitudinal Early‐onset Alzheimer's Disease Study (LEADS) and Alzheimer's Disease Neuroimaging Initiative (ADNI) study and tested for associations with AD risk, cognitive performance, and imaging and fluid biomarkers. RESULTS Though PGS was elevated in LOAD and EOAD, it was not a significant predictor of EOAD adjusting for APOE ε4 carrier status and was not associated with age of EOAD onset ( p = 0.106) or with cognitive performance ( p = 0.417). In LEADS, greater LOAD PGS was associated with differences in neuroimaging and fluid biomarkers, including elevated synaptosomal‐associated protein 25 (SNAP‐25) ( p = 2.3 × 10 −5 ). DISCUSSION While LOAD polygenic risk contributed minimally to EOAD onset and cognitive dysfunction, PGS association with fluid biomarkers in LEADS suggests a role for LOAD polygenic risk in EOAD pathophysiology. Highlights LOAD PGSs were elevated in both LOAD and EOAD compared to controls; however, LOAD PGS did not significantly predict EOAD risk, age at onset, or cognitive performance independent of APOE ε4 in the LEADS. Higher LOAD PGS was associated with lower amyloid PET Centiloids (less brain amyloid deposition) as well as lower CSF biomarker Aβ42 in LEADS (proxy marker suggesting higher brain amyloid deposition) in LEADS; these contradictory findings support the need for larger studies to further investigate whether LOAD PGS is associated with increased amyloid deposition in EOAD. Higher LOAD PGS was also associated with higher levels of CSF synaptosomal‐associated protein 25 (SNAP‐25), a key component of the SNARE complex, suggesting that LOAD genetic factors may contribute to dysregulation of synaptic transmission and/or pathological protein aggregation in EOAD.
Erosive Mucocutaneous Eruptions in Patients Treated With Immune Checkpoint Inhibitors: A Case Series
Jaroenpuntaruk, Valerie , Johnson, Emma F. , Phillips, Elizabeth J., Alavi, Afsaneh, Alavi, Afsáneh , Cull, Deborah B, Johnson, E F , Alavi, A , Cull, Deborah , Phillips, Elizabeth J.

Mayo Clinic

International Journal of Dermatology | January 14, 2026 | Volume: 65 | Issue: 7 | Pages: 1512-1515

10.1111/ijd.70279 | PMID 41531100 Get It

A State Blueprint to Equip Schools With a Uniform Overdose Response Strategy
Geyer, Holly L. , Renszel, Krystal, Kirkilas, Gary, Johnson, Catharina, Moffit, Randy, Kurtenbach, Mike, Geyer, Holly, Renszel, Krystal

Mayo Clinic

Pediatrics | January 14, 2026 | Volume: 157 | Issue: 2 | Pages: No page available

10.1542/peds.2025-072575 | PMID 41529810 Get It

With most states lacking comprehensive legislation addressing overdose preparedness in schools, there is an urgent necessity for prompt and effective solutions that accommodate existing resource constraints. Arizona, the primary entry point for over 55% of US fentanyl trafficking, responded to this critical public health challenge by initiating the nation’s first unfunded grassroots collaboration between community and government sectors to enhance statewide school overdose prevention and preparedness. The School Training, Overdose Preparedness and Intelligence Task force (STOP-IT) included more than 60 volunteers from the health care, legal, education, local government and behavioral health fields and worked collaboratively with the Arizona Department of Education to develop a response. Within 6 months of inception, STOP-IT conducted a comprehensive school survey to identify barriers to naloxone accessibility, created evidence-based school policies, established a sustainable and complimentary naloxone supply chain for schools with an ordering platform, and implemented a statewide naloxone distribution plan. The amassed resources were organized into a Fentanyl and Overdose Response Toolkit, widely disseminated to more than 2000 public, private, and charter schools. Moreover, STOP-IT launched both a local and national public information campaign to effectively raise awareness about the opioid crisis in schools. Using various media channels such as webinars, podcasts, media broadcasts, newsletters, and peer-reviewed publications, the campaign successfully amplified its message and enhanced community engagement. The STOP-IT initiative emerged as an innovative collaboration between government and community leaders, united in their mission to combat the growing opioid crisis in schools.
Outcomes After Colon Conduit Urinary Diversion: A Multi-Institutional Retrospective Study From the Reconstruction and Diversion: Improving Outcomes Group
Hebert, Kevin , Swinney, Seth , Johnson, Ryan, Ramsay, Joemy M. , Fendereski, Kiarad , DeWitt-Foy, Molly , Bearrick, Elizabeth , Maymi-Castrodad, Patricia, Stoffel, John T. , Seyer, A, McCormick, Benjamin J. , Myers, JeremyB, Hebert, Kevin J , Ramsay, Joemy , Bearrick, Elizabeth , Maymi-Castrodad, Patricia , Stoffel, John T , Seyer, Amanda, Viers, Boyd R , McCormick, Benjamin J , Myers, Jeremy B , Elliott, Sean, Viers, Boyd R.

Mayo Clinic

Journal of Urology | January 13, 2026 | Volume: 215 | Issue: 5 | Pages: 621-632

10.1097/ju.0000000000004935 | PMID 41529173 Get It

P-1228. Posaconazole Oral Suspension vs. Crushed Delayed-Release Tablets: Probability of Pharmacokinetic Target Attainment with Enteral Tube Administration
Bhattarai, Nirjan , O’Connell, Casey, Robinson, John, Cole, Kristin, Johnson, Tanner M , Stevens, Ryan W W, Wieruszewski, Patrick M. , Ilges, Dan , Stevens, Ryan W.

Mayo Clinic

Open Forum Infectious Diseases | January 12, 2026 | Volume: 13 | Issue: Supplement_1 | Pages: No page available

10.1093/ofid/ofaf695.1420 Get It

Abstract Background Posaconazole immediate release (IR) suspension is the standard product for enteral feeding tube (EFT) administration but has erratic pharmacokinetic behavior and results in sub satisfactory concentrations. Limited evidence suggests that the posaconazole oral delayed-release (DR) tablets may be crushed. Methods This was a retrospective cohort study of hospitalized adults who received EFT administration of posaconazole IR suspension or crushed DR tablets between 2018 and 2024. Patients were eligible if they had at least one serum concentration drawn ≥5 days after posaconazole initiation. The primary outcome was the attainment of therapeutic (≥700ng/mL for prophylaxis, ≥1,000ng/mL for treatment) serum concentration within 30 days. Secondary outcomes included time to therapeutic serum concentration, adverse drug effects, and frequency of clogged EFT. Multivariable cox proportional hazards regression was used to assess the relationship between posaconazole formulation and attainment of therapeutic concentrations while adjusting for confounding variables. Results Of the included patients, 100 received DR tablets and 48 received IR suspension. There were no significant differences in baseline characteristics or severity of illness. Among DR tablet and IR suspension recipients, 59% and 23% achieved therapeutic concentrations, respectively (p < 0.001). After adjusting for age, sex, BMI, drug interactions, posaconazole indication, malabsorptive gastrointestinal conditions, IR suspension was significantly less likely than crushed DR tablets to achieve therapeutic posaconazole concentrations within 30-days (HR 0.37, 95% CI 0.20-0.71; p < 0.003). The crushed DR tablet group required less total daily posaconazole to achieve therapeutic concentrations (400 vs 600 mg/day, p = 0.003). Clogged EFTs were more frequent in the crushed DR tablet group (27% vs 10%, p = 0.022), while no differences were observed in the occurrence of hepatotoxicity or hypokalemia. Conclusion Administration of crushed posaconazole DR tablets via EFT is more likely to attain therapeutic concentrations compared to IR suspension. The optimal technique for administering crushed DR tablets to prevent EFT complications warrants investigation. Disclosures Patrick M. Wieruszewski, PharmD, FCCM, Wolters Kluwer/UpToDate: Advisor/Consultant
MTAP Deletion in Oncogenesis: A Synthetic Lethality Scenario
Rodon, Jordi, Johnson, Melissa L. , George, Ben , Shah, Pooja A. , Arbour, Kathryn C. , Rodon, Jordi , Johnson, Melissa L

Mayo Clinic

Cancer Research | January 9, 2026 | Volume: 86 | Issue: 7 | Pages: 1558-1569

10.1158/0008-5472.can-25-2126 | PMID 41512197 Get It

Abstract Homozygous deletions in the gene encoding methylthioadenosine phosphorylase (MTAP) occur in ∼10% of patients with cancer, including up to 45% in some tumor types, and may be associated with poor prognosis. MTAP deficiency causes accumulation of its catabolic target methylthioadenosine (MTA) that outcompetes S-adenosyl methionine (SAM) for binding to protein arginine methyltransferase 5 (PRMT5), partially inhibiting PRMT5 activity as a posttranslational regulator of a variety of critical cellular functions. Prior anticancer treatments developed to target PRMT5 exhibited high rates of dose-limiting hematologic toxicities because of a lack of selectivity for tumor cells. More recently, several agents have been developed that exploit the vulnerability of MTAP-deleted cancer cells to further inhibition of the PRMT5 pathway, selectively inducing synthetic lethality in those cancer cells. MTA-cooperative PRMT5 inhibitors such as BMS-986504/MRTX1719 and AMG 193 target the PRMT5–MTA complex, whereas inhibitors of the SAM synthetase methionine adenosyl transferase 2A, such as IDE397, deprive PRMT5 of its methyl donor SAM. In this review article, we summarize the mechanisms of action, preclinical data, and clinical data available thus far for these novel classes of oncology precision medicine and discuss potential future directions relevant to MTAP deletion as a promising synthetic lethal vulnerability for cancer therapy.
Calibration of multi‐site raters for prospective visual read of amyloid PET scans acquired across the ADRC Consortium for Clarity in ADRD Research Through Imaging (CLARiTI)
Soleimani‐Meigooni, David N., Joie, Renaud La, Lin, Zoe, Soppe, Carol L., Johnson, Derek R., Koran, Mary Ellen I. , Villemagne, Victor L., Windon, Charles C., Mormino, Elizabeth C., Johnson, Sterling C, Rabinovici, Gil D., Windon, Charles , Windon, Charles , Soleimani‐Meigooni, David N. , Blazhenets, Ganna , Joie, Renaud La , Johnson, Derek R., McConathy, Jonathan , Nasrallah, Ilya M. , Tanner, Jeremy A. , Villemagne, Victor L. , Zeineh, Michael , Mormino, Elizabeth C. , Johnson, Sterling C. , Rabinovici, Gil D.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_107616 Get It

Abstract Background PET visual reads for multi‐center studies are conducted centrally by one or a few experts. In CLARiTI, a broader network of raters will perform the reads, necessitating methods to ensure their accuracy and reliability. Method All ADRC sites ( N = 37) will prospectively acquire amyloid PET scans for 800 cognitively unimpaired and 1200 cognitively impaired participants. Each site can use one of four amyloid PET tracers ([ 18 F]florbetaben, [ 18 F]florbetapir, [ 11 C]PIB, [ 18 F]NAV4694). PET scans will be visually interpreted by ten PET neuroimaging experts located across eight ADRCs, using their preferred hardware, software, and file format (DICOM, NIFTI). Calibration requires readers to perform blinded, independent visual interpretation of 180 amyloid PET scans (30 unique and 15 duplicate scans per tracer), previously read and selected by an expert (Table 1). An even mix of visually non‐elevated and elevated scans were selected, with quantitation spanning ‐26‐123 Centiloids (Figure 1), and 15% were visually borderline (similar proportion to ADNI4), with quantitation spanning 4‐48 Centiloids (mean 21). Kruskal‐Wallis H test showed no significant difference in the distribution of Centiloid values for scans in each tracer group, Χ 2 (3)=2.133, p = 0.545. Result Calibration scans were read by a second expert not serving in CLARiTI. There was 97% concordance and almost perfect agreement between readers (κ=0.932, p <0.001; Figure 2). Discordantly read scans were visually borderline elevated ( N = 2), borderline non‐elevated ( N = 1), and negative ( N = 1), with quantitation of 8‐21 Centiloids (mean 14). Intra‐rater reads were 98% concordant and had almost perfect agreement (κ=0.966, p <0.001). These findings hold promise for scaling‐up visual reads in CLARiTI, and we expect ≥80% concordance and substantial to almost perfect agreement (κ≥0.7) for inter/intra‐rater reliability. Conclusion Calibration is essential for accurate/reliable amyloid PET visual reads in large multi‐center studies with multiple raters. Through the calibration process, we will develop methods to improve the adjudication of borderline/challenging scans and formalize methods for visual reads of amyloid PET tracers that are investigational (i.e., [ 11 C]PIB, [ 18 F]NAV4694). Involving multiple raters across different sites, who use diverse hardware/software/file format combinations, will mirror the natural heterogeneity present in real‐world clinical practice. This calibration set can also serve as a standardized training tool for other studies incorporating amyloid PET visual reads.
Lost fractures: prevalence and risk factors for missed costosternal and costal cartilage fractures among patients with radiologic chest wall injury
Forrester, Joseph D , Chaar, Mohamad Abou, Barnes, Andrew T, Bauman, Zachary M, Bendjemil, Samy, Betts, Nizama N, Christie, Benjamin, Dasari, Raaga, WB, Devoe, Earley, Michelle J., Faliks, Bradley , Johns, Tracy J, Johnson, Connie, Junker, Michelle S., Kim, B. D., King, Jonathan, Knight, Ariel W. , Schweibinz, Alexis, Stephens, Daniel, Stuever, Mary, Wang, Simeng , Forrester, Joseph D. , Chaar, Mohamad K. Abou , Stephens, Daniel , Abou Chaar, Mohamad , Kim, Brian D. , King, Jonathan M , Knight, Ariel Whitney , Bauman, Zachary Mitchel , DeVoe, William B. , Johns, Tracy J. , Stuever, Mary, Stephens, Daniel

Mayo Clinic

Trauma Surgery & Acute Care Open | January 9, 2026 | Volume: 11 | Issue: 1 | Pages: e002020

10.1136/tsaco-2025-002020 | PMID 41561394 Get It

Background Costosternal cartilages and the costal margin, collectively termed costal cartilage, are hyaline cartilage connecting ribs to the sternum and to adjacent ribs, respectively. Presence of intact costal cartilage is essential for elasticity of the chest wall. Anecdotally, costal cartilage injuries are underdiagnosed on trauma CT scan in patients with rib fractures. Our aim was to determine a baseline frequency of acute costal cartilage injury among patients presenting with rib fractures. Methods We performed a retrospective cohort study of injured adult patients admitted to Level I/II trauma centers with rib fractures from January 2020 to July 2024. CT images obtained at admission were manually reviewed by chest wall surgeons for presence of costal cartilage injury. Concordance with the original radiology report was obtained. Multivariable regression was used to analyze factors associated with costal cartilage injury and missed cartilage fractures. Results 1441 patients were identified; 197 (14%) had a costal cartilage fracture. A plurality of injuries included falls (n=667, 46%). Median ISS (Injury Severity Score) was 13 (IQR: 9 to 21), median Abbreviated Injury Scale thorax score was 3 (IQR: 3 to 3), and median number of fractured ribs was 3 (IQR: 3 to 7). 294 (21%) patients had radiographic flail segments, and 136 (9%) had sternal fractures. 172 (87%) patients had a costal cartilage fracture missed on initial trauma chest CT. On multivariable analysis, ISS (adjusted OR (aOR) 1.02 (95% CI 1.01 to 1.04), radiographic flail segment (aOR 1.6 (95% CI 1.10 to 2.31)) and presence of sternal fracture (aOR 1.85 (95% CI 1.19 to 2.89)) were associated with costal cartilage fractures. Only the total number of rib fractures was associated with a missed costal cartilage fracture on univariate analysis (OR 1.17 (95% CI 1.01 to 1.36)). Conclusions Costal cartilage injuries are common and frequently are not identified during interpretation of the initial trauma CT. A higher index of suspicion is warranted for costal cartilage fractures among patients with greater injury burden, radiographic flail segment, and sternal fractures. Level of evidence Level III.
Using the Quality Outcomes Database to Identify Minimum Clinically Important Differences for Patients With Cervical Spondylotic Myelopathy
Asher, Anthony L., Lakomkin, Nikita, Mummaneni, Praveen V., Michalopoulos, Giorgos D., Johnson, Sarah E. , Park, Paul J. , Gottfried, Oren N., Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y., Knightly, John J. , Shaffrey, Christopher I., Virk, Michael S. , Fu, Kai-Ming, Tumialán, Luis M. , Turner, Jay D., Uribe, Juan S., Upadhyaya, Cheerag D., Shaffrey, Mark E., Coric, Domagoj , Chou, Dean, Haid, Regis W., Ef, Bisson, Bydon, Mohamad, Katsos, Konstantinos, Asher, Anthony L. , Lakomkin, Nikita , Mummaneni, Praveen V. , Michalopoulos, Giorgos D. , Park, Paul, Asher, Anthony M. , Katsos, Konstantinos, Wang, Michael Y. , Shaffrey, Christopher I. , Fu, Kai-Ming, Turner, Jay D. , Uribe, Juan S. , Chou, Dean , Bisson, Erica F. , Bydon, Mohamad

Mayo Clinic

Neurosurgery | January 9, 2026 | Volume: 98 | Issue: 6 | Pages: 1347-1358

10.1227/neu.0000000000003902 | PMID 41511085 Get It

BACKGROUND AND OBJECTIVES: Minimum clinically important differences (MCIDs) for patient-reported outcome metrics (PROMs) in patients with cervical spondylotic myelopathy (CSM) lack consensus on the most appropriate calculation method. This retrospective study aimed to identify the optimal MCIDs for commonly used PROMs in CSM. METHODS: The CSM database from the Quality Outcomes Database SpineCORe Study Group was analyzed. Baseline, 3-month, and 24-month PROM values for Neck Disability Index (NDI), 5-dimension Euro-quality of life (EQ-5D) in quality-adjusted life years, modified Japanese Orthopaedic Association (mJOA) score, and neck/arm pain numeric rating scale (NRS) were collected. MCIDs were calculated for each PROM using previously validated techniques. MCID values were compared using the area under the curve (AUC) with the North American Spine Society satisfaction scale as an anchor. RESULTS: A total of 1141 patients with CSM undergoing surgery were included in this analysis. Improvement of ≥30% from baseline was the optimal MCID for NDI and neck/arm NRS. At 24 months, the optimal percentage cutoff MCID for these instruments resulted in AUCs of 0.76, 0.72, and 0.67, similar to the 30% improvement method, with AUCs of 0.73, 0.71, and 0.67, respectively. Numeric cutoffs (0.065 at 3 months; 0.149 at 24 months) were the superior MCIDs for EQ-5D. For mJOA score, a severity-adjusted MCID outperformed other methods, yielding an AUC of 0.67 at 24 months. MCIDs were achieved in 63% of patients for NDI, 59% for neck pain NRS, 61% for arm pain NRS, 52% for EQ-5D, and 59% for mJOA score at 24 months. CONCLUSION: Using the Quality Outcomes Database SpineCORe data set, we defined optimal MCIDs for key PROMs in CSM. A ≥30% improvement from baseline was optimal in NDI and arm/neck NRS. An absolute numeric cutoff was superior for EQ-5D (0.149 at the 24-month follow-up). A severity-adjusted MCID performed best for mJOA score. These redefined benchmarks better capture the treatment impact and guide care decisions for patients with CSM.